Evidence-Based Oncology > January 2020

Evidence-Based Oncology - January 2020

January 19, 2020 – Mary Caffrey
Coverage from the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, featured results for allogeneic or "off the shelf" CAR T-cell treatments and bispecific antibodies. 
January 19, 2020 – Mary Caffrey
A pair of interviews on investigational therapies whose sponsors reported updates at the 61st American Society of Hematology Annual Meeting and Exposition: UCART19 from Servier and a revamped anti-BCMA therapy ide-cel from bluebird bio.
January 20, 2020 – Mary Caffrey
Results from clinical trials presented at the 2019 American Society of Hematology Annual Meeting and Exposition in Orlando, Florida. 
January 20, 2020 – Maggie L. Shaw and Mary Caffrey
Reviews of apixaban in active cancer, Medicare costs after CAR T-cell therapy, and the need for financial assistance for novel therapies.
January 21, 2020 – Maggie L. Shaw
Symptom burden, functional ability, and quality of life are necessary considerations when treating hematologic malignancies in older patients.
January 21, 2020 – Mary Caffrey
The abstract presented by Kwanza Price, MPH, of Jazz Pharmaceuticals, gathered data from August 1, 2017, and February 28, 2019, capturing the first 19 months of claims data after the biotech received FDA approval for its fixed-dose therapy for 2 types of poor-prognosis acute myeloid leukemia.
January 21, 2020 – Kelly Davio
Results for Truxima, recently launched in the United States, and complement inhibitors were presented at the 61st American Society of Hematology Annual Meeting and Exposition.
January 22, 2020 – Produced by Laura Joszt and Matthew Gavidia
Interviews with researchers and opinion leaders that took place during the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, December 7-10, 2019.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.